An anti-diabetes herbal drug has been launched by a Council of Scientific and Industrial Research (CSIR) lab in Lucknow, India, according to a report from The Times of India.
The drug, named BGR-34, has been developed to treat type 2 diabetes by two CSIR laboratories: National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP).
What is BGR-34?
Dr. AKS Rawat, senior principal scientist at NBRI, reports that BGR-34 is a combination of natural extracts from four plants mentioned in Ayurveda – an Indian holistic treatment that developed around 4000 years ago.
The drug can help control blood glucose levels, reduce the risk of diabetes-related complications, boost the immune system, and work as an antioxidant – protecting or delaying against cell damage.
Rawat added that clinical trials on animals have demonstrated 67 per cent success of BGR-34, and that the drug has no side effects. It will be available in the form of tablets and can be purchased in India within two weeks, according to V S Kapoor, marketing head of Aimil Pharmaceuticals.
Limitations
It is currently unclear how BGR-34 was tested in the reported clinical trials involving animals. It is also unknown if the drug has been studied on humans.
More information is required to assess why BGR-34 reduces blood glucose levels, and if it can be taken alongside existing medication.
There is no confirmation as to whether BGR-34 will be available in the UK.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…